Genocea Biosciences Inc. sell StockNews.com
Summary
This prediction was cancelled by the user.Genocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - |
| iShares Core DAX® | 3,90 % | 2,67 % | 5,69 % | 53,46 % |
| iShares Nasdaq 100 | -2,60 % | -7,93 % | 19,50 % | 72,28 % |
| iShares Nikkei 225® | -0,54 % | -9,75 % | 46,05 % | 63,08 % |
| iShares S&P 500 | -0,88 % | -1,49 % | 16,91 % | 60,40 % |
Comments by StockNews_com for this prediction
In the thread Genocea Biosciences Inc. diskutieren
In the thread Trading Genocea Biosciences Inc.